Harnessing the power of reimagination. It's how Ortho Clinical Diagnostics has been transforming in vitro diagnostics for more than 75 years. It's made us a trusted partner of hospitals, hospital networks, blood banks, and labs around the world. And today it's empowering us to advise our customers as they prepare for what's next.


From our earliest work in blood typing to the latest developments in laboratory systems, we've pioneered life-impacting advances. Scientific advances that have helped medical professionals diagnose conditions early and make better-informed treatment decisions. Our legacy inspires us every day and continues to drive us forward.


Our purpose is simple: to improve and save lives with diagnostics. We do that by reimagining what's possible. It's what defines us. It's the Ortho difference.

Ortho Clinical Diagnostics At A Glance

  • A global in vitro diagnostics leader
  • Founded in 1939
  • More than 75 years of pioneering life-impacting advances in diagnostics
  • Became a stand alone organization in 2014
  • Brings high-quality products and services to the global clinical laboratory and immunohematology communities
  • Supports hospitals, hospital networks, laboratories, and blood banks around the world
  • Provides sophisticated, simple, and intuitive testing technologies to clinical laboratories to help make lab processes more efficient and improve and patient care.
  • Supports the immunohematology community with blood typing products to help ensure every patient receives blood that is safe, the right type and the right unit
  • ~$1.8 billion in annual revenue
  • More than 4,400 employees worldwide
  • Global headquarters are in Raritan, N.J. Global Center of Excellence for R&D is in Rochester, N.Y. 
  • Provides 24/7 remote support through Predictive Technologies Centers


Chris Smith


Global Headquarters

Ortho Clinical Diagnostics
1001 Route 202
Raritan, NJ, 08869 US

© Ortho Clinical Diagnostics 2019. Ortho Clinical Diagnostics, publishes this site and is solely responsible for its content. The availability of the products is subject to compliance with the regulatory requirements of each market.